Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancer cells expressing abnormal carbohydrates (glycans) including ovarian, pancreatic, prostate, colon, breast and other solid tumors. These highly cancer specific, tumor associated carbohydrate antigens (TACAs) are present in the majority of solid tumors, and are exploited by tumor cells to suppress immune function, enable tissue invasion and metastasis, and promote a stem-cell phenotype. Therefore, therapeutic antibodies targeting TACAs have the potential to not only kill cancer cells but also re-engage the immune system and inhibit critical biological functions in cancer progression.
Siamab has developed a technology platform that enables the discovery of large numbers of highly specific, high affinity, anti-TACA therapeutic antibodies. Siamab's core technologies were licensed from the laboratory of Dr. Ajit Varki (UCSD), a world expert in glycobiology and sialic-acid biochemistry. Siamab has brought together a world-leading team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support our anti-TACA antibody discovery and development programs.
October 8, 2014
Siamab Therapeutics Appoints Robert Mashal to Board of Directors; Receives SBIR grant focused on cancer stem cells; Research to be conducted in collaboration with Massachusetts General Hospital